ERBB2 and breast carcinoma: In other work, HER2 sCAR-T cells proved that the in vitro toxicity was specific against different HER2-expressing breast cancer cell lines (HER2 3+, 2+, and 1+, measured by immunohistochemistry) and that it was comparable to classical HER2-CAR-T cells [310].